Prostate Cancer

The FDA has told AstraZeneca and MSD that the agency will extend the Prescription Drug User Fee Act date by 3 months to provide further time for a full review of the supplementary new drug application for olaparib plus abiraterone and prednisone or prednisolone for patients with mCRPC.

Daniel J. George, MD, discusses the clinical benefits of evaluating phenotype in metastatic castration-resistant prostate cancer.

The European Commission has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in combination with androgen deprivation therapy with or without androgen receptor pathway inhibition, for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Centering discussion on the use of cabazitaxel in metastatic CRPC, key opinion leaders consider optimal sequencing of therapy in light of the TROPIC clinical trial.

Expert oncologists Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, reflect on the current treatment paradigm for patients with metastatic castration-resistant prostate cancer (mCRPC).

Daniel J. George, MD, discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations.

Treatment with lutetium Lu 177 vipivotide tetraxetan led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival following treatment with an androgen receptor pathway inhibitor in patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Six months of enzalutamide monotherapy in combination with salvage radiation therapy postponed prostate-specific antigen progression compared with SRT alone in men with PSA-recurrent, high-risk prostate cancer.

The United Kingdom’s Medicines and Healthcare products Regulatory Agency has approved darolutamide tablets in combination with androgen deprivation therapy and docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Daniel J. George, MD, discusses the clinical implications use of key trials in metastatic castration-resistant prostate cancer.

Treatment developments in advanced prostate cancer are hinging on the benefits of triplet therapy and individualized care, the results of which are also informing treatment sequencing.

Emerging technologies such as PSMA-PET and magnetic resonance imaging, as well as increasingly refined molecular tests, are strengthening the prostate cancer treatment landscape.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of olaparib in combination with abiraterone acetate and prednisone or prednisolone for use in adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not indicated.

Emmanuel Antonarakis, MD, discusses the benefits of somatic and germline testing for patients with prostate cancer.

All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications.

For patients with metastatic castration-resistant prostate cancer who experience disease progression on novel hormonal agents (NHAs) and androgen deprivation therapy, it is important to consider when the NHA was received and whether docetaxel has been administered, as these factors affect downstream options and sequencing.

As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.

Because androgen deprivation therapy alone or with docetaxel is not recommended for most patients with metastatic castration-sensitive prostate cancer, a decision must be made between leveraging couplets vs triplets.

David Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

Emmanuel Antonarakis, MD, discusses the different therapeutic agents that are available for patients with metastatic castration-resistant prostate cancer who display either somatic or germline mutations.

Neal Shore, MD, discusses the importance of incorporating genetic testing into treatment strategies for patients with prostate cancer.

David Albala, MD, discusses integrating PSMA-PET imaging into the clinic and determining which patients with prostate cancer are prime candidates.

Neal Shore, MD, FACS, highlights the effect of genetic testing on the treatment paradigm of prostate cancer and the evolving treatment landscape for metastatic castration resistant prostate cancer.

The Chemotherapy Foundation Symposium® returns to New York City for its 40th annual meeting with a 3-day program that will deliver the latest updates across the gamut of oncology care.

The FDA has approved leuprolide acetate injection for use in the palliative treatment of patients with advanced prostate cancer.

Stephanie Berg, DO, discusses two key clinical trials that have advanced the standard of care in metastatic hormone-sensitive prostate cancer.

Christopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.

PARP inhibitors have emerged as agents that generate improved oncological outcomes in select patient populations with metastatic castration-resistant prostate cancer.

Darolutamide plus androgen-deprivation therapy and docetaxel elicited an overall survival benefit over placebo plus ADT and docetaxel in Black and African American patients with metastatic hormone-sensitive prostate cancer similar to the benefit observed in the overall population of the ARASENS trial.

A regimen comprised of radiation and intermittent hormone therapy (HT) resulted in an improvement in progression-free survival in patients with oligometastatic prostate cancer, according to data from the phase 2 EXTEND trial.